Tag Archives: NASDAQ:TNXP

Tonix Pharma was Downgraded to a Hold Rating at B.Riley FBR

B.Riley FBR analyst David Buck downgraded Tonix Pharma (NASDAQ: TNXP) to Hold yesterday and set a price target of $1.25. The company’s shares closed yesterday at $1.35, close to its 52-week low of $0.89. According to TipRanks.com, Buck is a

The COO of Tonix Pharma (NASDAQ: TNXP) is Buying Shares

Today, the COO of Tonix Pharma (NASDAQ: TNXP), MORRIS JESSICA EDGAR, bought shares of TNXP for $1,257. Following this transaction MORRIS JESSICA EDGAR’s holding in the company was increased by 22.42% to a total of $6,716. In addition to MORRIS

A Director at Tonix Pharma (NASDAQ: TNXP) is Selling Shares

Today, a Director at Tonix Pharma (NASDAQ: TNXP), Ernest Mario, sold shares of TNXP for $129.8K. The company has a one-year high of $9.40 and a one-year low of $2.85. Currently, Tonix Pharma has an average volume of 65.78K. Ernest

Roth Capital Reiterates a Hold Rating on Tonix Pharma

In a report released today, Scott Henry from Roth Capital reiterated a Hold rating on Tonix Pharma (NASDAQ: TNXP), with a price target of $0.60. The company’s shares opened today at $0.50, close to its 52-week low of $0.35. Henry

Tonix Pharma Receives a Hold from Oppenheimer

Oppenheimer analyst Jay Olson reiterated a Hold rating on Tonix Pharma (NASDAQ: TNXP) today. The company’s shares closed last Friday at $0.46, close to its 52-week low of $0.35. Olson wrote: “TNXP announced the FDA has granted Breakthrough Therapy Designation

Analysts Offer Insights on Healthcare Companies: Tonix Pharma (NASDAQ: TNXP) and Aptose Biosciences (NASDAQ: APTO)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Tonix Pharma (NASDAQ: TNXP) and Aptose Biosciences (NASDAQ: APTO). Tonix Pharma (NASDAQ: TNXP) In a report released today, Scott Henry from Roth Capital